Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on TaskUs, Lowers Price Target to $24

Baird Maintains Outperform on TaskUs, Lowers Price Target to $24

Baird analyst David Koning maintains TaskUs (NASDAQ:TASK) with a Outperform and lowers the price target from $34 to $24.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Baird analyst David Koning maintains TaskUs (NASDAQ:TASK) with a Outperform and lowers the price target from $34 to $24.

Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?

By Vandana Singh

November 27, 11:01 AM

Tharimmune Inc (NASDAQ: THAR) released phase 1 data with TH104, a proprietary

THAR

PaxMedica Holds Important FDA Type-B Meeting To Review PAX-101 Pivotal Trial Data; Key Guidance Regarding NDA Filing Obtained

By Benzinga Newsdesk

October 26, 8:05 AM

Key Guidance Regarding NDA Filing Obtained PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company, announced the completion of a type-B meeting with the FDA. During the live meeting, the company

PXMD

Analyst Ratings

Where Upwork Stands With Analysts

By Benzinga Insights

May 2, 3:00 PM

Analysts’ ratings for Upwork (NASDAQ:UPWK) over the last quarter vary from bullish to bearish, as provided by 8…

UPWK

Price Over Earnings Overview: ABB

By Benzinga Insights

May 12, 9:17 AM

In the current market session, ABB Inc. (NYSE:ABB) stock price is at $36.73, after a 0.01% decrease. However,…

ABB

Baird Maintains Outperform on TaskUs, Lowers Price Target to $24

Related Posts

Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?

PaxMedica Holds Important FDA Type-B Meeting To Review PAX-101 Pivotal Trial Data; Key Guidance Regarding NDA Filing Obtained

Where Upwork Stands With Analysts

Price Over Earnings Overview: ABB